Floatz logo

IVICENTAMAB

Diffuse Large B-cell Lymphoma

Genmabmonoclonal_antibodyPhase 1/2Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
73/ 100

Competitive context

271 Active assets in the Diffuse Large B-cell Lymphoma cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 2/3A
Evomela
Ruijin Hospital
Phase 4BBB
Axicabtagene Ciloleucel
Ruijin Hospital
Phase 4BBB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 3BBB
Inno-206
Beth Israel Deaconess Medical Center
Phase 4BBB

View all 50 →

Same molecule, other indications

IVICENTAMAB is also rated in:

primary mediastinal large B-cell lymphomaDormant
CC
Indicative ·
47 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
CC
Indicative ·
45 / 100
View asset →
marginal zone lymphomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →